These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35140339)

  • 1. Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma.
    Makino T; Yamasaki M; Tanaka K; Yamashita K; Urakawa S; Ishida T; Shiraishi O; Sugimura K; Miyata H; Motoori M; Fujitani K; Takeno A; Hirao M; Kimura Y; Satoh T; Yano M; Eguchi H; Doki Y; Yasuda T
    Br J Cancer; 2022 Jun; 126(11):1555-1562. PubMed ID: 35140339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
    Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
    Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial.
    Shiraishi O; Makino T; Yamasaki M; Tanaka K; Yamashita K; Ishida T; Sugimura K; Miyata H; Motoori M; Fujitani K; Takeno A; Hirao M; Kimura Y; Satoh T; Yano M; Doki Y; Yasuda T
    Esophagus; 2021 Oct; 18(4):825-834. PubMed ID: 33738656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
    Kato K; Machida R; Ito Y; Daiko H; Ozawa S; Ogata T; Hara H; Kojima T; Abe T; Bamba T; Watanabe M; Kawakubo H; Shibuya Y; Tsubosa Y; Takegawa N; Kajiwara T; Baba H; Ueno M; Takeuchi H; Nakamura K; Kitagawa Y;
    Lancet; 2024 Jul; 404(10447):55-66. PubMed ID: 38876133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute.
    Sato Y; Mori K; Atsumi S; Sakamoto K; Oya S; Okamoto A; Urabe M; Miwa Y; Yajima S; Yagi K; Nomura S; Yamashita H; Seto Y
    Esophagus; 2024 Oct; 21(4):514-522. PubMed ID: 38987434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma.
    Hirose T; Yamamoto S; Honma Y; Yokoyama K; Hirano H; Okita N; Shoji H; Iwasa S; Takashima A; Ishiyama K; Oguma J; Daiko H; Maeda S; Kato K
    Esophagus; 2024 Jul; 21(3):328-335. PubMed ID: 38467986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
    Yamagata Y; Saito K; Hirano K; Oya M
    World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).
    Goto H; Oshikiri T; Kato T; Nagatani Y; Funakoshi Y; Koterazawa Y; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Minami H; Kakeji Y
    PLoS One; 2024; 19(4):e0299742. PubMed ID: 38635652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
    Mitani S; Kawakami H; Shiraishi O; Kanemura H; Suzuki S; Haratani K; Hayashi H; Yonesaka K; Chiba Y; Yasuda T; Nakagawa K
    Esophagus; 2023 Apr; 20(2):281-289. PubMed ID: 36484900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).
    Nakamura K; Kato K; Igaki H; Ito Y; Mizusawa J; Ando N; Udagawa H; Tsubosa Y; Daiko H; Hironaka S; Fukuda H; Kitagawa Y;
    Jpn J Clin Oncol; 2013 Jul; 43(7):752-5. PubMed ID: 23625063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis.
    Kitadani J; Ojima T; Hayata K; Goda T; Takeuchi A; Tominaga S; Fukuda N; Nakai T; Yamaue H; Kawai M
    Oncology; 2024; 102(3):228-238. PubMed ID: 37708864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
    Umeki Y; Matsuoka H; Fujita M; Goto A; Serizawa A; Nakamura K; Akimoto S; Nakauchi M; Tanaka T; Shibasaki S; Inaba K; Uyama I; Suda K
    Intern Med; 2023; 62(3):319-325. PubMed ID: 36725064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
    Shiraishi O; Kato H; Momose K; Hiraki Y; Yasuda A; Shinkai M; Imano M; Yasuda T
    Oncology; 2023; 101(3):203-212. PubMed ID: 36599320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
    Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
    BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
    Matsuda S; Kitagawa Y; Takemura R; Okui J; Okamura A; Kawakubo H; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
    Ann Surg; 2023 Jul; 278(1):e35-e42. PubMed ID: 35837977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.